EpiCast Chronic Kidney Disease - Epidemiology forecast to 2022 (http://www.reportsnreports.com/reports/267725-epicast-chronic-kidney-disease-epidemiology-forecast-to-2022.html ) report provides an overview of the risk factors and the global and historical trends for CKD in the 6MM.
Dallas, Texas (PRWEB) September 02, 2013
Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. CKD affects people of all ages; however, the risk is higher in people ages 65 years and older. Globally, the estimated prevalence of CKD is 7.2% in adults over the age of 30 years. The disease is more common in women than men, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin. Based on the glomerular filtration rate, the Kidney Disease Outcomes Quality Initiative (KDOQI) classified CKD into five stages in 2002. Each stage of CKD requires different tests and treatments for management of the disease.
Purchase a report copy @ http://www.reportsnreports.com/Purchase.aspx?name=267725 .
This report provides an overview of the risk factors and the global and historical trends for CKD in the 6MM. In addition, the report includes a 10-year epidemiological forecast (2012–2022) of the prevalent cases of CKD segmented by sex, age (in five-year increments beginning at age 20 and ending at age 85 years), and stage in these markets. The number of Chronic Kidney Disease (CKD) cases across the US and 5EU will increase from 69.5 million in 2012 to 81 million in 2022, driven mainly by the growing prevalence of conditions such as hypertension, diabetes and obesity.
The latest report states that by 2022, the number of CKD cases in the US, France, Germany, Italy, Spain, and UK combined will increase by 1.62%. The US and Germany will have the largest CKD patient populations by the end of the forecast period, with an estimated 46 million and 12 million people affected by the disease, respectively.
Furthermore, the condition is more common in people of African and South Asian origin, due to the high hypertension rates in those of African heritage and the significant numbers of diabetes sufferers in South Asia.
Senior Epidemiologist says: Diabetes is the major risk factor for CKD because it is associated with significant cardiovascular morbidity and mortality. This is due to the high concentration of glucose in the blood for long periods of time, which overloads the kidneys as they work harder to filter the blood more often. When the kidneys fail in the advanced stages of CKD, patients are advised to undergo renal replacement therapy (RRT), which includes renal dialysis and kidney transplantation to sustain and maintain their lives. Such treatments have also proven to benefit blood pressure, and the balance of chemicals for the functioning of the heart and muscles, as well as the production of vitamin D and red blood cells.
A major strength of this analysis is the use of country-specific data and a uniform methodology across all the markets to forecast the prevalent cases of CKD. In addition, Epidemiologists provide segmentation of the CKD prevalent cases by stage per the KDOQI guidelines in each market, despite the stage-specific data being limited to certain age groups and stages.
Scope of this report
The Chronic Kidney Disease EpiCast report provides an overview of the risk factors and global trends of chronic kidney disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (2012–2022) of the prevalent cases of chronic kidney disease segmented by age (in five-year increments beginning at age 20 and ending at age =85 years), sex, and stage (1–5) in the 6MM
The chronic kidney disease epidemiology report was written and developed by Masters- and PhD-level epidemiologists
In-depth, high quality, transparent and market-driven, is providing expert analysis of disease trends in the 6MM.
Reasons to Buy
Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
Quantify patient populations in the global chronic kidney disease market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for V therapeutics in each of the markets covered.
Identify the percentage of chronic kidney disease prevalent cases that are in stages 1, 2, 3, 4, and 5.
Complete report available @ http://www.reportsnreports.com/reports/267725-epicast-chronic-kidney-disease-epidemiology-forecast-to-2022.html .
Browse more reports on Healthcare Market @ http://www.reportsnreports.com/market-research/healthcare/ .
About Us:
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers. Reported by PRWeb 2 days ago.
Dallas, Texas (PRWEB) September 02, 2013
Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. CKD affects people of all ages; however, the risk is higher in people ages 65 years and older. Globally, the estimated prevalence of CKD is 7.2% in adults over the age of 30 years. The disease is more common in women than men, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin. Based on the glomerular filtration rate, the Kidney Disease Outcomes Quality Initiative (KDOQI) classified CKD into five stages in 2002. Each stage of CKD requires different tests and treatments for management of the disease.
Purchase a report copy @ http://www.reportsnreports.com/Purchase.aspx?name=267725 .
This report provides an overview of the risk factors and the global and historical trends for CKD in the 6MM. In addition, the report includes a 10-year epidemiological forecast (2012–2022) of the prevalent cases of CKD segmented by sex, age (in five-year increments beginning at age 20 and ending at age 85 years), and stage in these markets. The number of Chronic Kidney Disease (CKD) cases across the US and 5EU will increase from 69.5 million in 2012 to 81 million in 2022, driven mainly by the growing prevalence of conditions such as hypertension, diabetes and obesity.
The latest report states that by 2022, the number of CKD cases in the US, France, Germany, Italy, Spain, and UK combined will increase by 1.62%. The US and Germany will have the largest CKD patient populations by the end of the forecast period, with an estimated 46 million and 12 million people affected by the disease, respectively.
Furthermore, the condition is more common in people of African and South Asian origin, due to the high hypertension rates in those of African heritage and the significant numbers of diabetes sufferers in South Asia.
Senior Epidemiologist says: Diabetes is the major risk factor for CKD because it is associated with significant cardiovascular morbidity and mortality. This is due to the high concentration of glucose in the blood for long periods of time, which overloads the kidneys as they work harder to filter the blood more often. When the kidneys fail in the advanced stages of CKD, patients are advised to undergo renal replacement therapy (RRT), which includes renal dialysis and kidney transplantation to sustain and maintain their lives. Such treatments have also proven to benefit blood pressure, and the balance of chemicals for the functioning of the heart and muscles, as well as the production of vitamin D and red blood cells.
A major strength of this analysis is the use of country-specific data and a uniform methodology across all the markets to forecast the prevalent cases of CKD. In addition, Epidemiologists provide segmentation of the CKD prevalent cases by stage per the KDOQI guidelines in each market, despite the stage-specific data being limited to certain age groups and stages.
Scope of this report
The Chronic Kidney Disease EpiCast report provides an overview of the risk factors and global trends of chronic kidney disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (2012–2022) of the prevalent cases of chronic kidney disease segmented by age (in five-year increments beginning at age 20 and ending at age =85 years), sex, and stage (1–5) in the 6MM
The chronic kidney disease epidemiology report was written and developed by Masters- and PhD-level epidemiologists
In-depth, high quality, transparent and market-driven, is providing expert analysis of disease trends in the 6MM.
Reasons to Buy
Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
Quantify patient populations in the global chronic kidney disease market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for V therapeutics in each of the markets covered.
Identify the percentage of chronic kidney disease prevalent cases that are in stages 1, 2, 3, 4, and 5.
Complete report available @ http://www.reportsnreports.com/reports/267725-epicast-chronic-kidney-disease-epidemiology-forecast-to-2022.html .
Browse more reports on Healthcare Market @ http://www.reportsnreports.com/market-research/healthcare/ .
About Us:
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers. Reported by PRWeb 2 days ago.